C
Craig R. Salhoff
Researcher at Eli Lilly and Company
Publications - 33
Citations - 2651
Craig R. Salhoff is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Agonist & Metabotropic glutamate receptor. The author has an hindex of 24, co-authored 33 publications receiving 2588 citations.
Papers
More filters
Journal ArticleDOI
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
James A. Monn,Matthew John Valli,Steven March Massey,Rebecca A. Wright,Craig R. Salhoff,Bryan G. Johnson,Trevor J. Howe,Charles A. Alt,Rhodes Gary Anthony,Roger L. Robey,Kelly R. Griffey,Joseph P. Tizzano,Mary Jeanne Kallman,David R. Helton,Darryle D. Schoepp +14 more
TL;DR: In this paper, the authors showed that 9 would closely approximate the bioactive conformation of glutamate when acting at group 2 metabotropic glutamate receptors (mGluRs) in the rat cerebral cortical slice.
Journal ArticleDOI
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
Eleni T. Tzavara,Richard J. Davis,Kenneth W. Perry,Xia Li,Craig R. Salhoff,Frank P. Bymaster,Jeffrey M. Witkin,George G. Nomikos +7 more
TL;DR: The results suggest that the cortical selectivity in the release of catecholamines, dopamine in particular, induced by the cannabinoid antagonist SR141716A, its procholinergic properties, together with its mild stimulatory effects on serotonin and norepinephrine efflux make similar compounds unique candidates for the treatment of psychosis, affective and cognitive disorders.
Journal ArticleDOI
3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus
TL;DR: In the rat hippocampus, 3,5‐dihydroxyphenylglycine can be used to activate subpopulations of mGluRs coupled to phosphoinositide hydrolysis with minimal effects on cAMP‐mGluR second messenger systems.
Journal ArticleDOI
LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
Darryle D. Schoepp,Bryan G. Johnson,Rebecca A. Wright,Craig R. Salhoff,Nancy Gail Mayne,Su Wu,S.L. Cockerham,J. Paul Burnett,Ramamoorthy Belegaje,David Bleakman,James A. Monn +10 more
TL;DR: LY354740 is a highly potent, efficacious and selective group II (mGlu2/3) receptor agonist, useful to explore the functions of these receptors in situ.
Journal ArticleDOI
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
Linda M. Rorick-Kehn,Bryan G. Johnson,Karen M. Knitowski,Craig R. Salhoff,Jeffrey M. Witkin,Kenneth W. Perry,Kelly I. Griffey,Joseph P. Tizzano,James A. Monn,David L. McKinzie,Darryle D. Schoepp +10 more
TL;DR: These results demonstrate the broad preclinical efficacy of LY404039 across multiple animal models of antipsychotic and anxiolytic efficacy and provides a novel mechanism for the treatment of psychiatric disorders that may be associated with improved efficacy and reduced incidence of undesirable side effects.